UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 313

Sortiert nach

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Annals of oncology, 2016-05, Vol.27 (5), p.856-861

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of Property Change Impacts Based on Requirements-Oriented, Multi-Criteria Decision Models

Proceedings of the Design Society, 2022-05, Vol.2, p.465-474

2022

Link zum Volltext

Verfügbarkeit prüfen

Choice of first line systemic treatment in pancreatic cancer among national experts

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2020-06, Vol.20 (4), p.686-690

2020

Link zum Volltext

Verfügbarkeit prüfen

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

European journal of cancer (1990), 2015-09, Vol.51, p.S194-S195

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Properties and Interactions with Blood Components of N 4-Hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) Incorporated into Liposomes

Journal of pharmacy and pharmacology, 2011-04, Vol.47 (4), p.282-288

2011

Link zum Volltext

Verfügbarkeit prüfen

Relevant Upstaging of Pn2 Cm0 Colorectal Cancer Patients with Post-Surgery 18F-Fdg Pet-Ct

Annals of oncology, 2014-09, Vol.25, p.iv196

2014

Link zum Volltext

Verfügbarkeit prüfen

Surgical Prevention of Weight Regain and Type 2 Diabetes Recurrence in 3 Different Bariatric Operations and Their Differential Long-Term Outcome

Annals of surgery open, 2021-06, Vol.2 (2), p.e053

2021

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) super()

Annals of oncology, 2016-05, Vol.27 (5), p.856-861

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice

British journal of cancer, 1997, Vol.75 (7), p.986-992

1997

Link zum Volltext

Verfügbarkeit prüfen

Health Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or Without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (Hcc)

Annals of oncology, 2014-09, Vol.25, p.iv358

2014

Link zum Volltext

Verfügbarkeit prüfen

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine

British journal of cancer, 1995-11, Vol.72 (5), p.1067-1073

1995

Link zum Volltext

Verfügbarkeit prüfen

New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens

Antiviral research, 1994-05, Vol.24 (1), p.79-93

1994

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer

European journal of cancer (1990), 1995-06, Vol.31 (6), p.1024-1024

1995

Link zum Volltext

Verfügbarkeit prüfen

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine

British journal of cancer, 1995-05, Vol.71 (5), p.957-962

1995

Link zum Volltext

Verfügbarkeit prüfen

CONCEPTUAL MODEL FOR (SEMI-) AUTOMATED DERIVATION OF EVALUATION CRITERIA IN REQUIREMENTS MODELLING

Proceedings of the Design Society: DESIGN Conference, 2020-05, Vol.1, p.937-946

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Properties and Interactions with Blood Components of N4-Hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) Incorporated into Liposomes

Journal of pharmacy and pharmacology, 1995-04, Vol.47 (4), p.282-288

1995

Link zum Volltext

Verfügbarkeit prüfen

Synthesis, and Some Properties of, Amphiphilic Dinucleoside Phosphate Derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT)

Antiviral chemistry & chemotherapy, 1994-12, Vol.5 (6), p.387-394

1994

Link zum Volltext

Verfügbarkeit prüfen

Cellular pharmacology of N4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937

Cancer chemotherapy and pharmacology, 1995, Vol.36 (6), p.483-492

1995

Link zum Volltext

Verfügbarkeit prüfen

573PRELEVANT UPSTAGING OF PN2 CM0 COLORECTAL CANCER PATIENTS WITH POST-SURGERY 18F-FDG PET-CT

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv196-iv197

2014

Link zum Volltext

Verfügbarkeit prüfen

1039PHEALTH ECONOMIC ANALYSIS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK 77/08: SORAFENIB WITH OR WITHOUT EVEROLIMUS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv358-iv358

2014

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Properties of N 4 -Hexadecyl- and N 4 - Octadecyl-1- β -D-Arabinofuranosylcytosine in Liposomal Preparations

Journal of liposome research, 1995, Vol.5 (1), p.27-47

1995

Link zum Volltext

Verfügbarkeit prüfen

Cellular pharmacology of a liposomal preparation of N super(4)-hexadecyl-1- beta -D-arabinofuranosylcytosine, a lipophilic derivative of 1- beta -D-arabinofuranosylcytosine

British journal of cancer, 1995-01, Vol.71 (5), p.957-962

1995

Link zum Volltext

Verfügbarkeit prüfen

Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne

Journal of cancer research and clinical oncology, 2000-06, Vol.126 (6), p.311

2000

Link zum Volltext

Verfügbarkeit prüfen

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-?-d-arabinofuranosylcytosine

Journal of cancer research and clinical oncology, 1996-02, Vol.122 (2), p.102-108

1996

Link zum Volltext

Verfügbarkeit prüfen

Oral antitumor activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine

Journal of cancer research and clinical oncology, 1996, Vol.122 (2), p.102-108

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 313

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(214)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(104)
Science & Technology
(66)
Life Sciences & Biomedicine
(57)
Female
(51)
Male
(43)
Adult
(41)
Sciences Biologiques Et Medicales
(31)
Sciences Medicales
(31)
Biological And Medical Sciences
(29)
Anesthesie. Reanimation. Transfusion. Therapie Cellulaire Et Therapie Genique
(26)
Anesthésie
(25)
Middle Aged
(24)
Child
(21)
Medical Sciences
(20)
Child, Preschool
(19)
Adolescent
(18)
Aged
(18)
Animals
(18)
Pharmacology. Drug Treatments
(14)
Pregnancy
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Identification of Property Change Impacts Based on Requirements-Oriented, Multi-Criteria Decision Models

Choice of first line systemic treatment in pancreatic cancer among national experts

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Pharmacokinetic Properties and Interactions with Blood Components of N 4-Hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) Incorporated into Liposomes

Relevant Upstaging of Pn2 Cm0 Colorectal Cancer Patients with Post-Surgery 18F-Fdg Pet-Ct

Surgical Prevention of Weight Regain and Type 2 Diabetes Recurrence in 3 Different Bariatric Operations and Their Differential Long-Term Outcome

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) super()

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice

Health Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or Without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (Hcc)

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-β-D-arabinofuranosylcytosine

New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens

Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer

Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine

CONCEPTUAL MODEL FOR (SEMI-) AUTOMATED DERIVATION OF EVALUATION CRITERIA IN REQUIREMENTS MODELLING

Pharmacokinetic Properties and Interactions with Blood Components of N4-Hexadecyl-1-β-d-arabinofuranosylcytosine (NHAC) Incorporated into Liposomes

Synthesis, and Some Properties of, Amphiphilic Dinucleoside Phosphate Derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT)

Cellular pharmacology of N4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937

573PRELEVANT UPSTAGING OF PN2 CM0 COLORECTAL CANCER PATIENTS WITH POST-SURGERY 18F-FDG PET-CT

1039PHEALTH ECONOMIC ANALYSIS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK 77/08: SORAFENIB WITH OR WITHOUT EVEROLIMUS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Preclinical Properties of N 4 -Hexadecyl- and N 4 - Octadecyl-1- β -D-Arabinofuranosylcytosine in Liposomal Preparations

Cellular pharmacology of a liposomal preparation of N super(4)-hexadecyl-1- beta -D-arabinofuranosylcytosine, a lipophilic derivative of 1- beta -D-arabinofuranosylcytosine

Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-?-d-arabinofuranosylcytosine

Oral antitumor activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine

Suchergebnisse filtern